Home > Resources > Videos > Gastrointestinal Diseases Drug Development Pipeline Review, 2018

Gastrointestinal Diseases Drug Development Pipeline Review, 2018

MarketResearchReports.com has announced the addition of “Gastrointestinal Diseases Drug Development Pipeline Review, 2018” research report to their offering.

Spotlight

MIPHARM SPA

Mipharm S.p.A. was born in January 1998 following the merger of Sandoz and Ciba Geigy, from which resulted the new company Novartis. Mipharm was founded by a group of ex managers coming from Novartis by mean of a spin-off of the manufacturing site located in Milan, Via Quaranta, previously owned by Sandoz. In December 2016, Mandarin Capital Partners II acquired the majority stake in Mipharm share capital. Today, Mipharm is one of the most valuable third-party manufacturing and new product development sites in Italy and it claims to have four FDA approvals (Nasal Spray Solution, Oral Potent Drug, Sachet, Packaging).

OTHER VIDEOS

The Cardinal Health™ InteLogix™ Platform

video | September 6, 2023

Learn about the industry’s first pharmaceutical supply chain solution that is reducing the cost of care and ensuring access to critical medications for hospitals and health systems....

Watch Now

Aeris: Benchtop XRD for pharmaceutical solid form analysis

video | August 28, 2023

Is solid form characterization critical in your line of work, but you lack expertise in X-ray diffraction (XRD)? Do you need an efficient tool to support you with lead optimization? Do you need an easy way to validate the stability of your solid form following processing?...

Watch Now

Semi-automated testing of on-body delivery systems (OBDS)

video | August 17, 2023

Injection systems that are attached to the patient's body (on-body delivery system OBDS) minimize possible risks, that can occur when drugs are administered by conventional needle-based injection systems (NIS)....

Watch Now

Line Optimizer - digital guided workflows for optimized pharma production operations

video | May 26, 2023

Connectivity in general is becoming an ever more important consideration for production facilities as we endeavour to produce more with less and all the while trying to satisfy an increasing need for more information and communication to and from the production equipment itself....

Watch Now

The Cardinal Health™ InteLogix™ Platform

video | September 6, 2023

Learn about the industry’s first pharmaceutical supply chain solution that is reducing the cost of care and ensuring access to critical medications for hospitals and health systems....

Watch Now

Aeris: Benchtop XRD for pharmaceutical solid form analysis

video | August 28, 2023

Is solid form characterization critical in your line of work, but you lack expertise in X-ray diffraction (XRD)? Do you need an efficient tool to support you with lead optimization? Do you need an easy way to validate the stability of your solid form following processing?...

Watch Now

Semi-automated testing of on-body delivery systems (OBDS)

video | August 17, 2023

Injection systems that are attached to the patient's body (on-body delivery system OBDS) minimize possible risks, that can occur when drugs are administered by conventional needle-based injection systems (NIS)....

Watch Now

Line Optimizer - digital guided workflows for optimized pharma production operations

video | May 26, 2023

Connectivity in general is becoming an ever more important consideration for production facilities as we endeavour to produce more with less and all the while trying to satisfy an increasing need for more information and communication to and from the production equipment itself....

Watch Now
MORE VIDEOS

Spotlight

MIPHARM SPA

Mipharm S.p.A. was born in January 1998 following the merger of Sandoz and Ciba Geigy, from which resulted the new company Novartis. Mipharm was founded by a group of ex managers coming from Novartis by mean of a spin-off of the manufacturing site located in Milan, Via Quaranta, previously owned by Sandoz. In December 2016, Mandarin Capital Partners II acquired the majority stake in Mipharm share capital. Today, Mipharm is one of the most valuable third-party manufacturing and new product development sites in Italy and it claims to have four FDA approvals (Nasal Spray Solution, Oral Potent Drug, Sachet, Packaging).

Events